In conclusion, our study provides evidence that routine gene test for the seven mutated genes, together with the evaluation of S100P/KRT17 expression and CA19-9 level, represent robust biomarkers to identify clinically and biologically distinct subtypes of ICC. The gene discussed is S100P; the disease is intrahepatic cholangiocarcinoma.